By David Tuller, DrPH A recent disability case in Norway provides a good example of why the draft of a new guideline for “long-term fatigue—including ME/CFS” is so problematic. As I reported last week, the draft guideline, produced by the Norwegian Directorate of Health*, generally favors the biopsychosocial approach. The guideline offers few specifics about …
By David Tuller, DrPH I posted a piece yesterday on Norway’s draft guideline for “long-term fatigue—including ME/CFS.” But my post was already outdated! The draft guideline was written by a team from the Norwegian Directorate of Health and is open for public comment until May 4th. A working group of 25 individuals from a range …
By David Tuller, DrPH On February 4th, the Norwegian Directorate of Health published a draft of a “national professional guideline” for diagnosis, management and treatment of “long-term fatigue—including ME/CFS.” A consultation period for the draft lasts for three months. All comments must be received by May 4th. The draft is intended to replace a 2015 …
By David Tuller, DrPH I often find myself responding to crap studies–such as a Norwegian study called “Brief Outpatient Rehabilitation Program for Post–COVID-19 Condition: A Randomized Clinical Trial,” from Nerli et al., published last December by JAMA Network Open. The senior author was Professor Vegard Wyller, the dean of the Norwegian wing of the CBT/GET/Lightning …
By David Tuller, DrPH *This is a crowdfunding month at University of California, Berkeley. If you appreciate my work and would like to make a donation (tax-deductible to US taxpayers) to the university in support of my position, here’s the link: https://crowdfund.berkeley.edu/project/46120 ********** “A small step in New Zealand” Sometimes there is modest good news. In …
By David Tuller, DrPH If the results for a trial’s primary outcome do not meet the threshold for what is considered a “clinically significant” benefit, it goes without saying—or at least it should–that investigators have no legitimate grounds for promoting their intervention as “effective.” This is especially true when the trial in question is unblinded …
